Sylvia Feyler

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · The Lancet · 2010 · 566 citations · Full text

Hematological Malignancy, Zoledronic Acid, Oncology +8

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Andy C. Rawstron, J. A. Child, Ruth M. de Tute et al. · Journal of Clinical Oncology · 2013 · 406 citations

The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells

Yasser M. El‐Sherbiny, Josephine Meade, Tim D. Holmes et al. · Cancer Research · 2007 · 310 citations · Full text

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · Blood · 2011 · 192 citations · Full text

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

Gareth J. Morgan, J. Anthony Child, Walter M. Gregory et al. · The Lancet Oncology · 2011 · 161 citations · Full text